The FDA has approved Axert (almotriptan malate tablets, from Ortho-McNeil Janssen), a selective 5-HT1B/1D receptor agonist, for the acute treatment of migraine headache in adolescents 12–17 years of age with a history of migraine attacks lasting ≥4 hours.

Axert is already indicated for the acute treatment of migraine in adults ≥18 years of age.

For more information call (800) 526-7736 or visit www.ortho-mcneilneurologics.com.